Bhatt RS - Search Results

1

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.

Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, Chen CH, Jegede OA, Catalano PJ, Pignon JC, Sticco-Ivins M, Zhu B, Hua P, Soden J, Zhu J, McDermott DF, Arulanandam AR, Signoretti S, Freeman GJ. Bhatt RS, et al. Cancer Immunol Res. 2021 Feb;9(2):156-169. doi: 10.1158/2326-6066.CIR-20-0315. Epub 2020 Nov 23. Cancer Immunol Res. 2021. PMID: 33229411 Free PMC article.

2

Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.

Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Gallagher DC, et al. Among authors: bhatt rs. Clin Cancer Res. 2007 Apr 1;13(7):2115-20. doi: 10.1158/1078-0432.CCR-06-2509. Clin Cancer Res. 2007. PMID: 17404094

3

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.

Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF. Cho DC, et al. J Immunother. 2009 Feb-Mar;32(2):181-5. doi: 10.1097/CJI.0b013e3181952b1d. J Immunother. 2009. PMID: 19238017

4

A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.

Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP. Bhatt RS, et al. Cancer. 2010 Apr 1;116(7):1751-6. doi: 10.1002/cncr.24902. Cancer. 2010. PMID: 20120033 Free PMC article. Clinical Trial.

5

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.

Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Bhatt RS, et al. Mol Cancer Ther. 2010 Oct;9(10):2793-802. doi: 10.1158/1535-7163.MCT-10-0477. Epub 2010 Aug 10. Mol Cancer Ther. 2010. PMID: 20699227 Free PMC article.

6

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS. Zhang L, et al. Among authors: bhatt rs. PLoS One. 2011 Apr 29;6(4):e19144. doi: 10.1371/journal.pone.0019144. PLoS One. 2011. PMID: 21559452 Free PMC article.

7

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.

Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS. Wang X, et al. Among authors: bhatt rs. J Transl Med. 2011 Dec 21;9:220. doi: 10.1186/1479-5876-9-220. J Transl Med. 2011. PMID: 22188900 Free PMC article.

8

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.

Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS. Wang X, et al. Among authors: bhatt rs. Br J Cancer. 2013 Feb 5;108(2):319-26. doi: 10.1038/bjc.2012.591. Epub 2013 Jan 15. Br J Cancer. 2013. PMID: 23322198 Free PMC article.

9

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. McDermott DF, et al. Among authors: bhatt rs. Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424850 Free PMC article. Clinical Trial.

10

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Zhang L, et al. Among authors: bhatt rs. Clin Cancer Res. 2015 Apr 15;21(8):1925-1934. doi: 10.1158/1078-0432.CCR-14-2031. Epub 2015 Jan 14. Clin Cancer Res. 2015. PMID: 25589614 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

159 results

Search Page